Home > Search Clinical Trials > All > Trial Details

Clinical Trial Details

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007) Clinical Trial ( IRB ) #: U26-070-1 Title: A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007) Principal Investigator: Dr. Nathaniel Robinson Description: This trial is testing MK 1084, an experimental drug, given with MK 3475A, an experimental combination and administration of drugs, in people who have nonsquamous non-small cell lung cancer (NSCLC) Classification:   Cancer - Lung Eligibility Criteria: Check with study contact How to Contact: Kristen Grandonico Telephone: Telephone: 860-679-6580. Email: grandonico@uchc.edu or Jillian Mcnamara Telephone: Telephone: 860-679-4581. Email: jimcnamara@uchc.edu Enrollment Status/Comments: Enrolling/recruiting.